Quick Answer
Tarsus Pharmaceuticals, Inc. reported Earnings Per Share Diluted of $1.59 (loss) per share for the year ending 2025.
- Tarsus Pharmaceuticals, Inc. showed an increase of +48.2% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Tarsus Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $0.74 (loss) per share | Q2 2020: $1.23 (loss) per share | Q3 2020: $3.71 (loss) per share | Q1 2021: $0.47 per share | Q2 2021: $0.29 per share | Q3 2021: $0.76 (loss) per share | Q1 2022: $0.98 (loss) per share | Q2 2022: $0.24 (loss) per share | Q3 2022: $0.84 (loss) per share | Q1 2023: $0.88 (loss) per share | Q2 2023: $1.17 (loss) per share | Q3 2023: $1.28 (loss) per share | Q1 2024: $1.01 (loss) per share | Q2 2024: $0.88 (loss) per share | Q3 2024: $0.61 (loss) per share | Q1 2025: $0.64 (loss) per share | Q2 2025: $0.48 (loss) per share | Q3 2025: $0.30 (loss) per share.
- Over the full 6 years of available data (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s Earnings Per Share Diluted has grown by 63.2%.
- Historical annual values: Fiscal year 2025: $1.59 (loss) per share | Fiscal year 2024: $3.07 (loss) per share | Fiscal year 2023: $4.62 (loss) per share | Fiscal year 2022: $2.52 (loss) per share | Fiscal year 2021: $0.67 (loss) per share | Fiscal year 2020: $4.32 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: